HLA-C and neoplasm: TCR therapy counters this by genetically modifying T cells to express specific TCRs that recognize peptide-MHC complexes, allowing them to target and respond to intracellular antigens even when presented by MHC molecules.458,459 This approach helps bypass the tumor’s evasion of immune detection by enhancing the recognition of altered or diminished antigen presentation on tumor cells, making the immune response more effective.